【作者】 洪志明； 陈德宁； 曾杨玲； 周文彬； 丁晓虹； 王全；

【Author】 HONG Zhiming;CHEN Dening;ZENG Yangling;ZHOU Wenbin;DING Xiaohong;WANG Quan;Shenzhen TCM Hospital;Guangzhou General Hospital of Guangzhou Military Area Command of Chinese PLA;

【机构】 深圳市中医院； 广州军区广州总医院；

【摘要】 目的:观察前痛定方治疗UPOINT表型分类属于T类的Ⅲ型慢性前列腺炎(CP)的临床疗效及安全性。方法:采用区组随机化方法,将120例Ⅲ型CP疼痛患者分为三组,G1组口服前痛定方,G2组口服塞来昔布胶囊,G3组口服塞来昔布胶囊+前痛定方,三组均连续治疗1月。观察三组患者治疗前、后的中医辨证评分和慢性前列腺炎症状指数(CPSI)的变化情况;检测患者前列腺液中的肿瘤坏死因子α(TNF-α)、白介素10(IL-10)、环氧化酶2(COX-2)水平;记录研究过程中出现的不良反应情况。结果:研究前,三组间基线特征均衡性良好,具有可比性。研究后,三组的组内比较和G1、G3组分别与G2组的组间比较的CPSI、疼痛症状评分、中医辨证评分、TNF-α、COX-2及IL-10水平较前研究比较均有统计学意义(P<0.05)。G1组与G3组所有指标经比较,其差异不具有统计学意义(P>0.05)。G1、G2、G3组总有效率分别为87.50%、62.50%和95.00%,经比较其差异具有统计学意义(P<0.05)。G1、G2、G3组总不良情况发生率分别为10.00%、12.50%和15.00%,经比较其差异不具有统计学意义(P>0.05)。结论:前痛定方对于经UPOINT分类属于T表型的Ⅲ型CP具有较好疗效,其安全性良好。更多还原

【Abstract】 Objective: To observe the effectiveness and safety of Qiantongding Decoction on the Type Ⅲ chronic prostatitis(CP)-induced pain classified with phenotypic classification system(UPOINT, urinary symptoms, psychosocial, organ-specific,infection, tenderness of pelvic floor skeletal muscles).Methods:In total 120 cases of Type Ⅲ CP-induced pain classified with UPOINT were randomized into treatment group(G1), control I group(G2) and control II group(G3). In G1,Qiantongding Decoction was orally applied; in G2, celecoxib capsule was orally used; and in G3, celecoxib capsule plus Qiantongding Decoction was orally taken, which lasted for continuous 1 month. Before and after treatments, the therapeutic effects of all the cases enrolled were assessed with National Institutes of Health-Chronic Prostatitis Symptom Index(CPSI) and CP syndrome differentiation scoring. The indexes such as tumor necrosis factor α(TNF-α), interleukin10(IL-10), cyclooxygenase 2(cox 2) in the prostatic fluid of patients were detected and all the adverse reactions during the treatments were recorded.Results: Before the study, the three groups had good baselines and comparability. After the study,compared with before treatments, there was significant difference of the CPSI scores, pain symptom scores, CP syndrome differentiation scores, the levels of the TNF-αand COX-2,and the level of IL-10(P<0.05). For the comparisons among the groups: Compared with the G2,There was significant difference of the clinical therapeutic effects among the three groups(P<0.05), with the G1 and G3 superior to G2. There was no significant difference of all the indexes between G1 and G3(P>0.05). The total effective rate in G1 was 87.50%, in G2 was62.5%, and in G3 was 95.00%. The adverse reaction rate in G1 was 10%,in G2 was 12.5%,and in G3 was 15.00%.There was no significant difference of the adverse reaction rate among the three groups(P=0.4627 > 0.05).Conclusions: Qiantongding Decoction has significantly clinical effect with safety on the Type Ⅲ CP-induced pain classified with UPOINT.更多还原